Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 15,824 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study Product Clear all

Conditions: Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm, Malignant Abdominal Neoplasm, Malignant Neck Neoplasm, Malignant Pelvic Neoplasm, Metastatic Childhood Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Near Infrared Imaging, Pafolacianine Sodium, Surgical Procedure; Procedure · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 6 Months to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions: Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P; Diagnostic Test · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Astrocytoma, Glioma
Interventions: 5-Aminolevulinic Acid; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumors
Interventions: TAS-102, Trifluridine; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Acute Mountain Sickness (AMS)
Interventions: T89 capsule, Placebo capsule; Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 853 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Heart Failure
Interventions: Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking; Drug · Device
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 29
States / cities: Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more

Conditions: Type1diabetes
Interventions: Regular insulin (Humulin-R), intranasal route, SipNose intranasal device; Drug · Device
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Sexually Transmitted Diseases
Interventions: Doxycycline; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: PF-04958242, Itraconazole; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: Drug: GB-102, Aflibercept; Drug
Lead sponsor: Graybug Vision; Industry
Eligibility: 50 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 33
States / cities: Gilbert, Arizona • Phoenix, Arizona • Bakersfield, California + 28 more

Conditions: Melanoma
Interventions: Ipilimumab, Chemotherapy; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 4 more

Conditions: Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions: Embospheres Microspheres; Device
Lead sponsor: Keith Pereira, MD:; Other
Eligibility: 22 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Select Advanced Solid Tumors
Interventions: Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors; Drug
Lead sponsor: Immunocore Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 17 more

Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma
Interventions: Olaparib Pill 50 mg, Olaparib Pill 100 mg, Olaparib Pill 150 mg, Olaparib Pill 200 mg, Olaparib Pill 250 mg, Olaparib Pill 300 mg, Radiotherapy; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: HER2-positive Breast Cancer, Breast Cancer, Breast Cancer Stage, Recurrent Breast Cancer, Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions: Palbociclib, T-DM1; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Tucson, Arizona • Beverly Hills, California • Aurora, Colorado + 12 more

Conditions: Solid Tumors
Interventions: Runimotamab, Trastuzumab, Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Saint Louis, Michigan • New York, New York + 2 more

Conditions: Neoplasms
Interventions: Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Chicago, Illinois • Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Hydromorphone Hydrochloride tablet 8 mg, Dilaudid® tablet 8 mg; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions: 18-NaF PET, DCE-MRI, 18-FDG PET/CT; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cocaine Dependence
Interventions: D-serine, Cognitive Behavioral Therapy, Placebo; Drug · Behavioral
Lead sponsor: Theresa Winhusen; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Decitabine, Dexamethasone, Palbociclib, Sorafenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Netherton Syndrome
Interventions: QRX003, 4% Lotion; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Skin Cancer
Interventions: DermDx; Device
Lead sponsor: MetaOptima Technology Inc.; Industry
Eligibility: Not listed
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: North Augusta, South Carolina

Conditions: Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions: Absorb BVS, XIENCE; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 98
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more

Search by objective public record fields.

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas

Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

IN Insulin in Type 1 Diabetes (T1D) Hypoglycemia Unawareness: Safety Only Phase

Doxy-Post-exposure Prophylaxis

A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Fasting Study of Hydromorphone Hydrochloride 8 mg Tablets and Dilaudid 8 mg Tablets

Imaging in MGUS, SMM and MM

D-Serine for Cocaine Dependence Pilot

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

Multi-Center Study to Evaluate the Performance of DermDx for Primary Care Physicians in the Detection of Skin Cancers

Absorb IV Randomized Controlled Trial